Core Viewpoint - Celcuity Inc's stock has surged by 221% to $43.76 following positive phase 3 trial results for its breast cancer therapy, gedatolisib, which is expected to receive FDA approval by year-end [1][2]. Group 1: Trial Results and Market Reaction - Gedatolisib, in combination with Pfizer's Ibrance and AstraZeneca's Faslode, reduced the risk of disease progression or death by 76% [2]. - The stock is trading at record highs, surpassing its previous all-time peak of $33.01 from June 25, 2021, and is now in positive territory year-over-year [2]. Group 2: Options Activity and Analyst Ratings - There is increased options activity, with puts outnumbering calls nine to one, indicating traders are betting on a potential correction [3]. - All eight analysts covering Celcuity have a "buy" or "strong buy" rating, although the 12-month consensus price target of $32 is now below current trading levels, which may support further bullish sentiment [3].